Brain : a journal of neurology · 2026
TIM-3-dependent lysosome biogenesis is required for myelin debris clearance in macrophages.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xiaodi, Xu Ziqing, Zhang Yingxue, Tong Zheng, Ren Xiaolei, Xiao Ying, Chen Hao, Han Na, Li Chunyang, Yue Xuetian, Wu Zhuanchang, Liang Xiaohong, Ma Chunhong, Wang Pin, Gao Lifen
Аннотация
Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by the immune-mediated demyelination and neurodegeneration of the central nervous system. Phagocyte mediated myelin debris clearance is required for remyelination. TIM-3 is highly expressed on mononuclear macrophages and promotes the phagocytosis of apoptotic cells. Here, we report that TIM-3 enhances the clearance of myelin debris in experimental autoimmune encephalomyelitis (EAE), a model of MS. Tim-3 knockout (KO) exacerbated EAE severity, neuroinflammation, and demyelination by regulating mononuclear macrophages. TIM-3 promoted the phagocytosis and degradation of myelin debris by macrophages. Mechanistically, Tim-3 deficiency impaired lysosomal biogenesis and function, leading to lysosomal membrane permeabilization and disrupted lysosomal acidification, which further exacerbated neuroinflammation and demyelination. Notably, TIM-3 blocked the interaction of mTOR-TFEB to inhibit TFEB phosphorylation and facilitate its nuclear translocation, followed by increased expression of lysosomal genes critical for myelin degradation. Importantly, the IgV domain is necessary in TIM-3-mediated lysosomal regulation and myelin degradation. These findings highlight TIM-3 as a key regulator of lysosomal homeostasis and the clearance of myelin debris, suggesting that the IgV domain has promise as a therapeutic agent for treating demyelinating diseases such as MS.